In a letter to shareholders, Moderna CEO Stéphane Bancel believes that the most optimistic five-year scenario set out in 2018 is coming true.

"As we reflect on the past year, our commitment to leveraging mRNA to deliver transformative medicines to patients has never been stronger", explains the executive, who says he has the platform, technology, resources and team in place to establish "a new era of medicine".

At the same time, the laboratory says it is preparing for the potential launch of its experimental vaccine against respiratory syncytial virus (RSV) in 2024.

Our objective for 2024 and 2025 is to boost sales growth and profitability", continues the manager. Stéphane Bancel expects to double the number of programs in phase 3 by 2025, and to launch up to 15 products in five years.

We expect to reach break-even in 2026, as revenues increase and late-stage R&D costs decrease, when the current large Phase 3 clinical trials come to an end and give rise to numerous potential new product launches", he concludes.

Following this announcement, the share price soared by over 13% in New York.


Copyright (c) 2024 CercleFinance.com. All rights reserved.